JNJ

233.01

+1.03%↑

ISRG

478.71

-3.54%↓

ABT

108.96

-0.46%↓

RDY

13.8

+1.55%↑

NEOG

10.27

+0.39%↑

JNJ

233.01

+1.03%↑

ISRG

478.71

-3.54%↓

ABT

108.96

-0.46%↓

RDY

13.8

+1.55%↑

NEOG

10.27

+0.39%↑

JNJ

233.01

+1.03%↑

ISRG

478.71

-3.54%↓

ABT

108.96

-0.46%↓

RDY

13.8

+1.55%↑

NEOG

10.27

+0.39%↑

JNJ

233.01

+1.03%↑

ISRG

478.71

-3.54%↓

ABT

108.96

-0.46%↓

RDY

13.8

+1.55%↑

NEOG

10.27

+0.39%↑

JNJ

233.01

+1.03%↑

ISRG

478.71

-3.54%↓

ABT

108.96

-0.46%↓

RDY

13.8

+1.55%↑

NEOG

10.27

+0.39%↑

Search

Pulse Biosciences Inc

Затворен

СекторЗдравеопазване

14.01 2.11

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

13.66

Максимум

14.33

Ключови измерители

By Trading Economics

Приходи

-217K

-19M

Продажби

86K

86K

EPS

-0.29

Марж на печалбата

-22,540.698

Служители

75

EBITDA

-228K

-19M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+71.41% upside

Дивиденти

By Dow Jones

Следващи печалби

26.03.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-179M

958M

Предишно отваряне

11.9

Предишно затваряне

14.01

Настроения в новините

By Acuity

55%

45%

285 / 352 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

Pulse Biosciences Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

3.02.2026 г., 23:11 ч. UTC

Значими двигатели на пазара
Придобивния, сливания и поглъщания

Silicon Laboratories Shares Up On Report of $7 Billion Texas Instruments Acquisition Deal

3.02.2026 г., 23:50 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

3.02.2026 г., 23:50 ч. UTC

Пазарно говорене

Nikkei May Decline After Hitting All-Time High -- Market Talk

3.02.2026 г., 23:42 ч. UTC

Пазарно говорене

Gold Edges Lower on Possible Technical Correction -- Market Talk

3.02.2026 г., 23:41 ч. UTC

Придобивния, сливания и поглъщания

KKR Makes AI Play With $10.9B Asia Data-Center Deal

3.02.2026 г., 23:38 ч. UTC

Печалби

AMD Sales Climb on Help From Data-Center Business -- Update

3.02.2026 г., 23:29 ч. UTC

Придобивния, сливания и поглъщания

KKR-Consortium Deal in STT GDC Is One of the Largest Digital-Infrastructure Transactions in Southeast Asia

3.02.2026 г., 23:27 ч. UTC

Придобивния, сливания и поглъщания

Netflix, Warner Defend Proposed Deal in Senate Hearing -- WSJ

3.02.2026 г., 23:25 ч. UTC

Придобивния, сливания и поглъщания

KKR-Consortium Expects Deal to Close by Early 2H of 2026

3.02.2026 г., 23:23 ч. UTC

Придобивния, сливания и поглъщания

KKR Consortium With Singtel to Own 75% and 25% Stake in ST Telemedia Global Data Centres

3.02.2026 г., 23:22 ч. UTC

Придобивния, сливания и поглъщания

KKR-Led Consortium to Buy Singapore-Based Global Data-Center Provider Valued at S$13.8B

3.02.2026 г., 23:19 ч. UTC

Пазарно говорене

Australia Gold Miners Tipped to Rally Higher -- Market Talk

3.02.2026 г., 23:19 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

3.02.2026 г., 22:56 ч. UTC

Значими двигатели на пазара
Придобивния, сливания и поглъщания

Silicon Laboratories Shares Up On Report of $7B Texas Instruments Acquisition Deal

3.02.2026 г., 22:40 ч. UTC

Печалби

Amdocs Extends Collaboration With T-Mobile

3.02.2026 г., 22:39 ч. UTC

Печалби

Amdocs 1Q Adj EPS $1.81

3.02.2026 г., 22:39 ч. UTC

Печалби

Amdocs 1Q Rev $1.16B

3.02.2026 г., 22:39 ч. UTC

Печалби

Amdocs 1Q EPS $1.45 >

3.02.2026 г., 22:38 ч. UTC

Печалби

Amdocs: Shimie Hortig to Succeed Shuky Sheffer as President and CEO, Effective March 31

3.02.2026 г., 22:30 ч. UTC

Придобивния, сливания и поглъщания

Bob Iger's Second Time as CEO Wasn't Great for the Stock. He Still Leaves Behind A Strong Legacy. -- Barrons.com

3.02.2026 г., 22:22 ч. UTC

Придобивния, сливания и поглъщания

Texas Instruments Nearing $7B Deal for Silicon Laboratories, Sources Tell FT

3.02.2026 г., 22:14 ч. UTC

Печалби

AMD Expects to Scale AI Business to Tens of Billions in Annual Sales in 2027, CEO Says

3.02.2026 г., 22:13 ч. UTC

Печалби

AMD Expects Data-Center Unit Sales to Jump More Than 60% a Year Over Next Three to Five Years, CEO Says

3.02.2026 г., 22:12 ч. UTC

Печалби

AMD in Talks With Several Companies About At-Scale, Multi-Year Chip Deployments, CEO Says

3.02.2026 г., 22:10 ч. UTC

Печалби

AMD CEO: Eight of 10 Biggest AI Companies Use Instinct Chip to Power Production Workloads

3.02.2026 г., 22:10 ч. UTC

Печалби

Blackstone Stock, Alternative Managers, BDCs Dive as Software Woes Infect Private Credit -- Barrons.com

3.02.2026 г., 22:10 ч. UTC

Пазарно говорене

Key Drivers Underpinning Shaw's Bullish View of Gold Intact -- Market Talk

3.02.2026 г., 22:10 ч. UTC

Печалби

AMD CEO: Enterprises Are Modernizing Data Centers to Have Compute Needed for New AI Workflows

3.02.2026 г., 22:09 ч. UTC

Печалби

AMD CEO: Hyperscalers Expanding Infrastructure to Meet Growing Cloud-Services Demand in AI

3.02.2026 г., 22:09 ч. UTC

Печалби

AMD CEO: Demand Accelerated Across Data Center, Gaming and PC

Сравнение с други в отрасъла

Ценова промяна

Pulse Biosciences Inc Прогноза

Ценова цел

By TipRanks

71.41% нагоре

12-месечна прогноза

Среден 23.5 USD  71.41%

Висок 25 USD

Нисък 22 USD

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за Pulse Biosciences Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

2 ratings

2

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

16.59 / 17.17Подкрепа & съпротива

Краткосрочен план

Very Strong Bearish Evidence

Средносрочен план

Bearish Evidence

Дългосрочен план

Weak Bearish Evidence

Настроение

By Acuity

285 / 352 Класиране в Здравеопазване

Настроения в новините

Мечи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Pulse Biosciences Inc

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
help-icon Live chat